Description
The cell line OE19, also known as JROECL19, was established in 1993 from an adenocarcinoma of gastric cardia/oesophageal gastric junction of a 72 year old male patient. The tumour was identified as pathological stage III and showed moderate differentiation. The cell line OE19 expresses HLA-A, -B and -C antigens constitutively. Treatment with interferon-gamma induced the expression of ICAM-1. Expression of HLA-DR on interferon-gamma addition was only measured in a sub-population of OE19. The cells express epithelial cytokeratins and are tumourigenic in nude mice.The Y chromosome could not be detected in this cell line by short tandem repeat-PCR analysis when tested at Glow Biologics. It cell line is a known phenomenon that due to the increased genetic instability of cancer cell lines the Y chromosome can be rearranged or lost resulting in lack of detection. The cell line is identical to the source provided by the depositor based on the STR-PCR analysis.
Adherent Suspension
Adherent
Suggested Medium
RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).
Quality Control
OE19 Cell Line was tested and found to be free of mycoplasma, bacterial, viruses, and other toxins. All cells were above 95% viability before freezing.
Tissue
Oesophagus/gastric cardia
Shippment
OE19 Cell Line will be shipped using dry ice.
Storage
Store the cell lines in liquid nitrogen vapor (less than -130°C)
Warranty
OE19 Cell Line is for research use only
